About PER-001 Intravitreal Implant, a Long-Acting Endothelin Receptor Antagonist PER-001 is a novel (new chemical entity), first-in-class small molecule endothelin receptor antagonist. Endothelin is ...

Bayer is handing over up to $2.45bn to acquire Perfuse Therapeutics – marking the company’s first bid to enhance its legacy in the ophthalmology market since the patent expiry of its best-selling eye ...

Bayer has struck a deal to buy Perfuse Therapeutics for $300 million upfront. The buyout, which includes up to $2.15 billion in milestones, will give Bayer control of an eye disease implant that ...

Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the ...

Bayer is paying $300 million to buy Perfuse Therapeutics, a clinical-stage biotech that offers a new growth opportunity in ophthalmology as the pharmaceutical company’s top eye product weathers ...

Bayer said on ​Wednesday that it will ‌buy biopharmaceutical company Perfuse Therapeutics to complement its ophthalmology ​pipeline.

Bayer BAYN0.55%increase; green up pointing triangle said it agreed to buy Perfuse Therapeutics for up to $2.45 billion, snapping up an eye-drug specialist that is developing a potential glaucoma ...